A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational ...

The NHS’ long term survival is at stake – the Ten Year Plan demonstrates the government’s commitment to invest in its recovery, but in order to truly tackle the existential issues at the heart of the ...

In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for ...

The purpose of this research is to identify the attributes to include in a value framework for orphan medicinal products (OMPs), determine their relative importance using a multi-criteria decision ...

This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted ...

Real-World Evidence (RWE) can provide decision-makers in the healthcare sector with insights into the functioning of health technologies outside of clinical trial settings. In this report, we focus on ...

Most value assessments of vaccination programs are carried out by taking the perspective of the health system. To stimulate the debate concerning the broader value of vaccination beyond this ...

The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS ...

In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement ...

In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of ...

It’s not often that you witness a health system reinvent itself in real-time. And yet, this is precisely what is happening across the Middle East.

This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most Favoured Nation’ drug pricing. We know that pegging US drug prices to the rest ...